Ontology highlight
ABSTRACT:
SUBMITTER: Byrd JC
PROVIDER: S-EPMC6058242 | biostudies-literature | 2018 Jul
REPOSITORIES: biostudies-literature
Byrd John C JC Ruppert Amy S AS Heerema Nyla A NA Halvorson Alese E AE Hoke Eva E Smith Mitchell R MR Godwin John E JE Couban Stephen S Fehniger Todd A TA Thirman Michael J MJ Tallman Martin S MS Appelbaum Frederick R FR Stone Richard M RM Robinson Sue S Chang Julie E JE Mandrekar Sumithra J SJ Larson Richard A RA
Blood advances 20180701 14
Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear. The role of lenalidomide was also not defined. This phase 2 study randomized 342 untreated patients with non-del(11q) CLL requiring therapy to fludarabine plus rituximab (FR; n = 123), FR plus lenalidomide consolidation (FR+L; n = 109), or FR plus cyclophosphamide (FCR; n = 110) and compared 2-year progression-free survival (PFS) rates of e ...[more]